Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The aim of the document is to provide practical, evidence-based guidelines for the diagnosis and treatment of Heart Failure.
3.1. Definition of heart failure
3.3. Epidemiology, aetiology and natural history of heart failure
4.1. Symptoms and signs
4.2. Essential initial investigations: natriuretic peptides, electrocardiogram, echocardiography
4.3. Algorithm for the diagnosis of heart failure
5.1. Chest X-ray
5.2. Transthoracic echocardiography
5.3. Transoesophageal echocardiography
5.4. Stress echocardiography
5.5. Cardiac magnetic resonance
5.6. Single-photon emission computed tomography and radionuclide ventriculography
5.7. Positron emission tomography
5.8. Coronary angiography
5.9. Cardiac computed tomography
5.10. Other diagnostic tests
7.1. Objectives in the management of heart failure
7.2. Treatments recommended in all symptomatic patients with heart failure with reduced ejection fraction
7.3. Other treatments recommended in selected patients with symptomatic heart failure with reduced ejection fraction
7.4. Other treatments with less-certain benefits in patients with symptomatic heart failure with reduced ejection fraction
7.5. Treatments not recommended (unproven benefit) in patients with symptomatic heart failure with reduced ejection fraction
7.6. Treatments not recommended (believed to cause harm) in patients with symptomatic heart failure with reduced ejection fraction
8.1. Implantable cardioverter-defibrillator
8.2. Cardiac resynchronization therapy
8.3. Other implantable electrical devices
9.1. Effect of treatment on symptoms in heart failure with preserved ejection fraction
9.2. Effect of treatment on hospitalization for heart failure in heart failure with preserved ejection fraction
9.3. Effect of treatment on mortality in heart failure with preserved ejection fraction
9.4. Other considerations
10.1. Atrial fibrillation
10.2. Ventricular arrhythmias
10.3. Symptomatic bradycardia, pauses and atrio-ventricular block
11.1. Heart failure and co-morbidities
11.2. Angina and coronary artery disease
11.3. Cachexia and sarcopenia
11.5. Central nervous system (including depression, stroke and autonomic dysfunction)
11.7. Erectile dysfunction
11.8. Gout and arthritis
11.9. Hypokalaemia and hyperkalaemia
11.12. Iron deficiency and anaemia
11.13. Kidney dysfunction (including chronic kidney disease, acute kidney injury, cardio-renal syndrome, and prostatic obstruction)
11.14. Lung disease (including asthma and chronic obstructive pulmonary disease)
11.16. Sleep disturbance and sleep-disordered breathing
11.17. Valvular heart disease
12.1. Definition and classification
12.2. Diagnosis and initial prognostic evaluation
12.4.Management of evidence-based oral therapies
12.5. Monitoring of clinical status of patients hospitalized due to acute heart failure
12.6. Criteria for discharge from hospital and follow-up in high-risk period
12.7. Goals of treatment during the different stages of management of acute heart failure
13.1. Mechanical circulatory support
13.2. Heart transplantation
14.1. Organization of care
14.2. Discharge planning
14.3. Lifestyle advice
14.4. Exercise training
14.5. Follow-up and monitoring
14.6. The older adult, frailty and cognitive impairment
14.7. Palliative /end-of-life care
© 2017 European Society of Cardiology. All rights reserved